Arsenic, cadmium, and selenium exposures and bone mineral density-related endpoints: The HORTEGA study

Gálvez-Fernández, Marta; Grau-Pérez, María; García‐Barrera, Tamara; Ramírez-Acosta, Sara; Gómez‐Ariza, José Luis; Pérez‐Gómez, Beatriz; Galan-Labaca, Iñaki; Navas‐Acien, Ana; Redón, Josep; Briongos-Figuero, Laisa Socorro; Dueñas‐Laita, Antonio; Pérez‐Castrillón, José Luis; Téllez-Plaza, María; Martı́n-Escudero, Juan Carlos

doi:10.1016/j.freeradbiomed.2020.10.318

Cited by 39 publications

(27 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, no association was found between Serum Se and fracture subjects from five European cities (37). This study found that dietary Se intake was positively associated with fracture, and the association was strengthened after dietary patterns were adjusted, which was consistent with the previously published study in Spain (20). In the longitudinal study in Hortega, HRs for fracture across the tertiles of plasma Se were 1, 1.09 (95% CI: 55-2.16), 1.67 (95% CI: 91-3.04), and the HR of fracture for 80th percentiles of plasma Se distribution was 2.25 (95% CI: 1.13-4.49) compared with the 20th in a model that adjusted for age, sex, BMI, education, physical activity, urine cotinine, glomerular filtration, smoking, and alcohol drinking (20).…”

Section: Discussionsupporting

confidence: 91%

“…The association between Se status and fracture is inconsistent. A longitudinal study in Spain showed that participants with higher Se intake had a significant risk of fracture (20). In contrast, a cross-sectional study in the United States found an inverse correlation between blood, serum, and dietary Se with the occurrence of fracture (22), which was subsequently confirmed by another two studies performed in the United States and China (38,39).…”

Section: Discussionmentioning

confidence: 92%

“…A cross-sectional study of 7,407 middle-aged and older women in the United States, and a case-control study on 107 postmenopausal women in Turkey did not find any association between high Se intake and risk of osteoporosis and BMD (17,19). A recent study on 1,365 Spanish adults (medium serum Se 84.9 µg/L at baseline) observed a U-shape dose-response relationship between serum Se and osteoporosis-related fracture (20). In contrast, a cross-sectional study in China argued that deficient dietary Se intake (<50 µg/day) is associated with higher prevalence of osteoporosis among 1,452 middle-aged and older people (21).…”

Section: Introductionmentioning

confidence: 92%

“…Low Se in hair and plasma is related to BMD reduction (17,18). However, inconsistent findings are reported on the association between Se intake and osteoporosis/fracture risk (17)(18)(19)(20)(21)(22). A cross-sectional study of 7,407 middle-aged and older women in the United States, and a case-control study on 107 postmenopausal women in Turkey did not find any association between high Se intake and risk of osteoporosis and BMD (17,19).…”

Section: Introductionmentioning

confidence: 99%

“…Meanwhile, existing evidence suggests that patients with T2DM or hypertension have an increased risk of fracture, suggesting that chronic diseases may mediate the association between Se intake and risk of fracture (29,30). Besides, Balvez-Fernandez et al observed a U-shape curve for BMD and fracture associated with the increment of serum Se with a turning point of 105 µg/L (20).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Higher Dietary Se Intake Is Associated With the Risk of New-Onset Fracture: A National Longitudinal Study for 20 Years

Zhang

Zhao

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

Background: The association between dietary selenium (Se) intake and osteoporosis-related fractures remains inconsistent. We aimed to examine the dose relationship between Se intake and incident fracture among Chinese adults.Methods: The dietary data were retrieved from the China Health and Nutrition Survey conducted between 1991 and 2011, and 17,150 participants aged above 20 were included. A 3-day, 24-h recall of food intake was performed to assess cumulative average dietary Se intake. The fracture was based on self-report in each survey between 1997 and 2011. The association between Se intake and fracture was tested by Cox regression, and the non-linear association was examined by restricted cubic splines (RCS).Results: There were 976 fracture cases during a mean of 10.2 years follow-up. In a fully adjusted Cox model, across the quartiles of Se intake, the hazard ratios (HRs) for fracture were 1.07 (95% CI .86–1.33), 1 (reference), 1.25 (95% CI 1.02–1.53), and 1.33 (95% CI 1.07–1.65). RCS showed a parabolic association (P non-linear = 0.037) between Se and fracture for men as well as a U-shape dose-response (P non-linear = 0.04) between Se and fracture for subjects living in highly urbanized areas.Conclusion: In conclusion, there is a non-linear association between selenium intake and fracture, with higher intake associated with increased risk. The shape of the association varies by gender and urbanization level.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Higher Dietary Se Intake Is Associated With the Risk of New-Onset Fracture: A National Longitudinal Study for 20 Years

Zhang

Zhao

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

show abstract

Chiral Selenium Nanotherapeutics Regulates Selenoproteins to Attenuate Glucocorticoid‐Induced Osteoporosis

Xiong

Lin

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Glucocorticoid (GC)-induced osteoporosis (GIO) is a concurrent disease commonly appeared in chronic inflammatory and autoimmune disease patients.Stereoselective recognition between chiral drugs and homochiral biological molecules could directly affect their distribution, adhesion and transport. Herein, trace element selenium (Se) with bone formation-regulating activity, is employed to construct cysteine-decorated chiral nanoparticles (Cys@SeNPs) to attenuate GIO. Interestingly, comparing with the racemic (DL-Cys@SeNPs) and D-Cys@SeNPs, the L-Cys@SeNPs displays higher uptake in osteoblast cells and could lessen reactive oxygen species overproduction to block dexamethasone (Dex)-induced osteoblasts cells apoptosis. Intracellular L-Cys@SeNPs could be predominantly transformed to selenocystine to upregulate the expression levels of antioxidative selenoproteins to effectively scavenge Dex-induced excessive ROS accumulation in osteoblasts, and thus reduce the undesirable apoptosis through activating Wnt/β-catenin pathway. Consistently, L-Cys@SeNPs significantly alleviates the main osteoporosis symptoms of bone trabeculae destruction and decreased bone density in vivo, and also reduces the weight gain and fatty liver formation in Dex-exposed mice, thus suppressing the overall side effects of Dex. This study not only demonstrates an effective strategy for treatment of GIO by using chiral Se nanomedicine, but also elucidates the important roles of selenoproteins in alleviating osteoporosis, which could help for future Se-based drug design through chirality control engineering.

show abstract

Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled Trial

Perri

Hill

Mathers

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the longterm impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N-terminal propeptide (PINP), collagen type I cross-linked C-telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60-74 years) were randomized to receive placebo-yeast versus 100, 200, or 300 μg selenium as selenium-enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose-response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo-treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health.

show abstract

Arsenic, cadmium, and selenium exposures and bone mineral density-related endpoints: The HORTEGA study

Cited by 39 publications

References 81 publications

Higher Dietary Se Intake Is Associated With the Risk of New-Onset Fracture: A National Longitudinal Study for 20 Years

Higher Dietary Se Intake Is Associated With the Risk of New-Onset Fracture: A National Longitudinal Study for 20 Years

Chiral Selenium Nanotherapeutics Regulates Selenoproteins to Attenuate Glucocorticoid‐Induced Osteoporosis

Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled Trial

Contact Info

Product

Resources

About